Insulin-like Growth Factor 1 Long R3, commonly known as IGF-1 LR3, is one of the most studied peptide analogs in modern biomedical research. As a modified form of endogenous IGF-1, this 83-amino acid peptide has attracted sustained scientific interest for its enhanced pharmacokinetic profile and potent biological activity across multiple tissue types.
For researchers investigating growth factor signaling, cellular proliferation, or metabolic regulation, IGF-1 LR3 offers a uniquely stable tool compound. This guide covers the molecular distinctions from native IGF-1, its mechanism of action, key preclinical findings, and practical research considerations — all framed strictly for research purposes only.
IGF-1 vs. IGF-1 LR3: key structural and functional differences
Understanding why IGF-1 LR3 matters to researchers requires appreciating what distinguishes it from the native peptide.
Native IGF-1 is a 70-amino acid peptide produced primarily in the liver in response to growth hormone (GH) stimulation. In circulation, over 95% of IGF-1 is bound to one of six IGF-binding proteins (IGFBPs), which regulate its bioavailability and half-life. Free IGF-1 has an estimated half-life of only 10–12 minutes in serum.
IGF-1 LR3 incorporates two critical modifications:
- Arginine substitution at position 3: The glutamic acid residue at position 3 is replaced with arginine (Glu3→Arg), significantly reducing binding affinity for IGFBPs. This keeps a much higher proportion of the peptide in its free, bioactive form.
- N-terminal extension: A 13-amino acid peptide extension is added to the N-terminus, further disrupting IGFBP recognition while preserving receptor binding affinity.
The result is a peptide with a functional half-life approximately 20–30 hours — a dramatic increase over native IGF-1. This extended bioavailability makes IGF-1 LR3 substantially more potent in cell culture and preclinical assay systems on a molar basis.
| Property | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| Amino acids | 70 | 83 |
| Half-life (estimated) | 10–12 minutes | 20–30 hours |
| IGFBP binding | High (>95% bound) | Very low |
| Relative potency (in vitro) | 1x | ~2–3x |
| Molecular weight | ~7,649 Da | ~9,111 Da |
Mechanism of action: how IGF-1 LR3 signals at the cellular level
IGF-1 LR3 exerts its biological effects primarily through binding to the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase expressed on virtually all mammalian cell types. The signaling cascade that follows receptor engagement is well-characterized and involves several major intracellular pathways.
The PI3K/Akt pathway
Upon IGF-1R activation, insulin receptor substrate (IRS) proteins are phosphorylated, recruiting and activating phosphoinositide 3-kinase (PI3K). PI3K generates PIP3 at the membrane, which recruits and activates Akt (protein kinase B). Akt phosphorylation drives:
- Protein synthesis — via activation of the mTOR (mechanistic target of rapamycin) complex, specifically mTORC1, leading to phosphorylation of p70S6K and 4E-BP1
- Anti-apoptotic signaling — through phosphorylation and inactivation of pro-apoptotic factors BAD and caspase-9
- Glucose uptake — via GLUT4 transporter translocation to the cell membrane
The MAPK/ERK pathway
IGF-1R activation also engages the Ras→Raf→MEK→ERK cascade. This pathway primarily drives cellular proliferation and differentiation, contributing to the mitogenic effects observed in preclinical IGF-1 LR3 studies.
mTOR signaling and protein synthesis
The convergence of PI3K/Akt signaling on mTORC1 is particularly relevant to researchers studying muscle biology. mTORC1 activation increases ribosomal biogenesis, cap-dependent mRNA translation, and net protein accretion — the molecular basis for the hypertrophic effects reported in preclinical models (Musaro et al., 2001; PMID: 11175789).
Research applications: what the preclinical literature shows
IGF-1 LR3 has been investigated across a wide range of biological systems. Below are the most established research domains, each supported by peer-reviewed preclinical evidence. All applications described are for research purposes only.
Muscle hypertrophy and regeneration
The role of IGF-1 signaling in skeletal muscle growth is among the best-characterized applications. Key findings include:
- Satellite cell activation: IGF-1 signaling promotes quiescent satellite cell activation, entry into the cell cycle, and fusion with existing myofibers — the primary mechanism of postnatal muscle hypertrophy (Adams & McCue, 1998; PMID: 9572822).
- Myoblast proliferation and differentiation: In C2C12 myoblast cultures, IGF-1 and its analogs promote both proliferation (via MAPK) and terminal differentiation into myotubes (via PI3K/Akt), with IGF-1 LR3 showing enhanced potency due to reduced IGFBP sequestration.
- Localized hypertrophy: Musaro et al. (2001) demonstrated that localized IGF-1 expression in transgenic mice produced significant skeletal muscle hypertrophy and maintained regenerative capacity during aging, establishing IGF-1 as a direct mediator of muscle mass regulation.
For a broader overview of peptides investigated in muscle growth research, see our Best Peptides for Muscle Growth Research guide.
Metabolic research
IGF-1 LR3 engages metabolic pathways that make it a useful tool compound in metabolic research:
- Glucose uptake: Through PI3K/Akt-mediated GLUT4 translocation, IGF-1 signaling promotes glucose uptake in skeletal muscle and adipose tissue independently of insulin, making it relevant to insulin resistance and type 2 diabetes research models.
- Lipid metabolism: Preclinical evidence suggests IGF-1 signaling enhances fatty acid oxidation and reduces lipogenesis in hepatocytes, pointing to potential roles in metabolic syndrome research (Clemmons, 2007; PMID: 17906644).
- Body composition: In rodent models, sustained IGF-1 activity is associated with increased lean mass and reduced adiposity, consistent with its role as an anabolic and lipolytic mediator.
Neuroprotection
The IGF-1 receptor is widely expressed in the central nervous system, and IGF-1 signaling has demonstrated neuroprotective properties in preclinical models:
- Neuronal survival: IGF-1/Akt signaling suppresses apoptosis in neuronal cell lines exposed to oxidative stress, excitotoxicity, and serum withdrawal, suggesting a pro-survival role (Bondy & Cheng, 2004; PMID: 15094070).
- Synaptic plasticity: IGF-1 modulates long-term potentiation (LTP) in hippocampal slice preparations, a cellular correlate of learning and memory.
- Neurodegenerative models: Reduced IGF-1 signaling is observed in animal models of Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), driving research interest in IGF-1 analogs as investigational neuroprotective agents.
Wound healing and tissue repair
IGF-1 signaling plays an established role in wound healing cascades:
- Fibroblast migration and proliferation: IGF-1 acts as a mitogen for dermal fibroblasts, promoting migration into wound beds and collagen deposition during the proliferative phase of repair.
- Angiogenesis: Preclinical studies indicate that IGF-1 promotes VEGF expression in wound tissue, supporting neovascularization.
- Bone and cartilage: IGF-1 signaling stimulates osteoblast proliferation and chondrocyte matrix synthesis, making it relevant to orthopedic and cartilage repair research.
IGF-1 LR3 in context: how it compares to gH-releasing peptides
Researchers often encounter IGF-1 LR3 alongside growth hormone-releasing peptides (GHRPs) and growth hormone-releasing hormone (GHRH) analogs. Understanding the distinction is important for experimental design.
| Feature | IGF-1 LR3 | GH-Releasing Peptides (e.g., GHRP-6, Ipamorelin) |
|---|---|---|
| Mechanism | Direct IGF-1R agonist | Stimulate endogenous GH secretion |
| Site of action | Peripheral tissues (direct) | Hypothalamus / pituitary (indirect) |
| IGF-1 elevation | Direct — bypasses GH axis | Indirect — via GH → hepatic IGF-1 production |
| Onset | Rapid (receptor binding) | Delayed (GH pulse → IGF-1 synthesis) |
| Feedback loop | Does not suppress GH secretion | Subject to hypothalamic feedback |
| Specificity | IGF-1R selective | Broad (GH affects multiple axes) |
For researchers, the key distinction is that IGF-1 LR3 acts downstream of the GH axis, allowing investigation of IGF-1-specific signaling without the confounding variables of growth hormone’s pleiotropic effects.
Research considerations: handling, storage, and reconstitution
Peptide integrity is critical for reproducible research results. IGF-1 LR3 requires careful handling:
Storage
- Lyophilized (unreconstituted): Store at -20°C or below. Lyophilized IGF-1 LR3 is stable for 24+ months when kept desiccated and protected from light.
- Reconstituted: Store at 2–8°C (refrigerated). Use within 30 days for optimal activity. Avoid repeated freeze-thaw cycles — aliquot into single-use volumes after reconstitution.
Reconstitution
- Reconstitute with sterile bacteriostatic water (0.9% benzyl alcohol) or sterile acetic acid (0.1M) depending on experimental requirements.
- Add solvent gently along the vial wall — do not vortex. Swirl gently until fully dissolved.
- For detailed reconstitution calculations, use our Peptide Reconstitution Calculator.
Stability factors
- IGF-1 LR3 is sensitive to pH extremes. Optimal stability is maintained at pH 3.0–5.0 in solution.
- Exposure to temperatures above 37°C accelerates degradation. Maintain cold chain throughout handling.
- For a deeper understanding of peptide degradation pathways, see our guide on Peptide Stability and Degradation.
Quality verification: ensuring research-grade purity
Peptide quality directly impacts experimental reproducibility. When sourcing IGF-1 LR3 for research, verify the following:
Certificate of analysis (COA)
Every batch should ship with a COA documenting purity, identity, and quality control testing. Key elements to verify:
- HPLC purity: Research-grade IGF-1 LR3 should demonstrate ≥98% purity by reverse-phase HPLC. This confirms the absence of synthesis byproducts, truncated sequences, and aggregates.
- Mass spectrometry (MS): Electrospray ionization mass spectrometry (ESI-MS) should confirm the molecular weight matches the theoretical mass of 9,111 Da (±2 Da), verifying correct sequence and modifications.
- Amino acid analysis: Quantitative amino acid composition confirms the peptide sequence and rules out substitution errors.
- Endotoxin testing: For in vivo research applications, bacterial endotoxin levels should be below 1 EU/mg as measured by the LAL (Limulus Amebocyte Lysate) assay.
For a detailed breakdown of analytical testing methods, see our guide on Peptide Purity Testing: HPLC & Mass Spectrometry.
CertaPeptides provides third-party verified COAs with every IGF-1 LR3 lot. Browse our IGF-1 LR3 product page or explore the full research catalog and Complete Lab Starter Kit.
Frequently asked questions
What is the difference between IGF-1 and IGF-1 LR3?
IGF-1 LR3 is a modified analog of native IGF-1 with an arginine substitution at position 3 and a 13-amino acid N-terminal extension. These modifications reduce binding to IGF-binding proteins, resulting in a longer functional half-life (20–30 hours vs. 10–12 minutes) and increased bioavailability for research applications.
What is the half-life of IGF-1 LR3?
IGF-1 LR3 has an estimated functional half-life of 20–30 hours, compared to approximately 10–12 minutes for native IGF-1. This extended activity is due to its dramatically reduced affinity for IGF-binding proteins (IGFBPs).
How should IGF-1 LR3 be stored?
Lyophilized IGF-1 LR3 should be stored at -20°C or below, protected from light and moisture. After reconstitution, store at 2–8°C and use within 30 days. Aliquot into single-use volumes to avoid freeze-thaw degradation.
What signaling pathways does IGF-1 LR3 activate?
IGF-1 LR3 binds the IGF-1 receptor and activates two primary cascades: the PI3K/Akt/mTOR pathway (driving protein synthesis and cell survival) and the MAPK/ERK pathway (driving cellular proliferation and differentiation).
Is IGF-1 LR3 the same as growth hormone?
No. IGF-1 LR3 acts downstream of growth hormone. While GH stimulates hepatic IGF-1 production, IGF-1 LR3 directly activates IGF-1 receptors without involving the GH axis. This makes it a more targeted tool for studying IGF-1-specific signaling in research settings.
What purity should research-grade IGF-1 LR3 have?
Research-grade IGF-1 LR3 should demonstrate ≥98% purity by HPLC, with identity confirmed by mass spectrometry (expected MW ~9,111 Da). A Certificate of Analysis (COA) with third-party verification ensures batch-to-batch reliability.
Can IGF-1 LR3 be used in cell culture?
Yes. IGF-1 LR3 is widely used in cell culture as a media supplement, particularly for serum-free or reduced-serum conditions. Its low IGFBP binding makes it more effective than native IGF-1 in culture systems where binding proteins would otherwise sequester the peptide.
This article is provided for educational and research purposes only. IGF-1 LR3 is sold exclusively as a research compound and is not intended for human consumption, therapeutic use, or diagnostic purposes. All research should comply with applicable institutional, local, and national regulations.
References
- Musaro A, McCullagh K, Paul A, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27(2):195-200. PMID: 11175789
- Adams GR, McCue SA. Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats. J Appl Physiol. 1998;84(5):1716-1722. PMID: 9572822
- Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007;6(10):821-833. PMID: 17906644
- Bondy CA, Cheng CM. Signaling by insulin-like growth factor 1 in brain. Eur J Pharmacol. 2004;490(1-3):25-31. PMID: 15094070
- Francis GL, Ross M, Ballard FJ, et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213-223. PMID: 1381175